Nutrition & Health
- Acquisition of Pronova BioPharma ASA responsible for significant sales growth
- Sales volumes grow in almost all business areas and regions
- Margin pressure, negative currency effects and higher fixed costs lead to considerable decline in earnings
Nutrition & Health – Sales by region (Location of customer)Enlarge image
In the Nutrition & Health division, sales to third parties rose by €129 million to €2,088 million in 2013. This considerable growth is attributable to the integration of the acquired Pronova BioPharma ASA business, a leading producer of omega-3 fatty acids. The sales increase was weakened by negative currency effects as well as by lower sales prices mainly resulting from sustained competitive pressure in the vitamins business (volumes 2%, prices –2%, portfolio 10%, currencies –3%).
With demand largely stable, we were able to raise our sales volumes in almost all business areas and regions. We posted the largest volumes growth in the pharmaceutical and flavor and fragrance business areas.
Despite the positive contribution from Pronova BioPharma, income from operations before special items was considerably below the level of 2012. This was largely because of rising margin pressure and negative currency effects. Fixed costs were higher than the previous year’s level, owing to increased research spending and higher production and selling expenses. Special charges arose from the integration of Pronova BioPharma and measures to increase our competitiveness.